Effects of IL-12 on human ovarian tumors engrafted into SCID mice

Gynecologic Oncology

Volumn 72, Issue 2, 1999, Pages 154-160

  Silver, David F ^a   Hempling, Ronald E ^a   Steven Piver, M ^a   Repasky, Elizabeth A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRAFT; CANCER GROWTH; CANCER REGRESSION; COMBINED IMMUNODEFICIENCY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCHEMISTRY; MOUSE; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; SPLEEN FUNCTION;

EID: 0032936207     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5239     Document Type: Article

References (19)

1. Thigpen PA, Blessing JA, Vance RB, Lambuth BW: Chemotherapy in ovarian carcinoma: present role and future prospects. Semin Oncol 16: 58-65, 1989
2. Cancer Facts and Figures - 1995. Atlanta, GA, American Cancer Society, 1995
3. Bookman MA: Biologic therapy in the management of refractory ovarian cancer. Gynecol Oncol 51:113-126, 1993
4. Bookman MA, Berek JS: Biologic and immunologic therapy of ovarian cancer. Hematol Oncol Clin North Am 6:941-965, 1992
5. Tahara H, Lotze MT: Antitumor effects of interleuken-12: applications for the immunotherapy and gene therapy of cancer. Gene Ther 2:96-106, 1995
6. Cavallo F, Signorelli P, Giovarelli M, Musiani P, Modesti A, Brunda MJ, Colombo MP, Forni G: Antitumor efficacy of adenocarcinoma cells engineered to produce interleuken-12 or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 89:1049-1058, 1997
7. Brunda MJ: Antitumor and antimetastatic activity of interleuken-12 against murine tumors. J Exp Med 178:1223-1230, 1993
8. Tan J, Newton CA, Djeu JY, Gutsch DE, Chang AE, Yang NS, Klein TW, Yu H: Injection of complementary DNA encoding interleuken-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res 56:3399-3403, 1996
9. Iwanuma Y, Chen FA, Egilmez NK, Takita H, Bankert RB: Antitumor response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice. Cancer Res 57:2937-2942, 1997
10. Majewski S, Marczak M, Szmurlo A, Jablonska S, Bollag W: Interleuken-12 inhibits angiogenesis induced by human tumor cell lines in vivo. J Invest Dermatol 106:1114-1118, 1996
11. Yoshida Y, Takasi K, Kimurai M, Takenaga K, Yamamoto H, Yamaguchi T, Saisho H, Sakiyama S, Tagawa M: Antitumor effect of human pancreatic cancer cells transduced with cytokine genes which activate Th1 helper T cells. Anticancer Res 18:333-336, 1998
12. Sartori A, Ma X, Gri G, Showe L, Benjamin D, Trinchieri G: Interleuken-12: an immunoregulatory cytokine produced by B cells and antigen-presenting cells. Methods 11:116-127, 1997
13. Trinchieri G: Interleuken-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells with type 1 and cytotoxic lymphocytes. Blood 84:4008-4027, 1994
14. Trinchieri G: Interleuken 12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13:251-276, 1995
15. Kagi D, Ledermann B, Burki K, Zinkernagel RM, Hengartner H: Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protectionand pathogenesis in vivo. Annu Rev Immunol 14:207-232, 1996
16. Xu Y, Silver DF, Yang NP, Rencuzogullari E, Hempling RE, Piver MS, Repasky EA: Characterization of human ovarian carcinomas in a SCID mouse model. Gynecol Oncol, 1998
17. Brunda MJ, Gately MK: Anti-tumor activity of interleuken-12. Clin Immunol Immunopathol 71:253-255, 1994
18. Hendrzak JA, Brunda MJ: Interleuken-12: biological activity, therapeutic utility and role in disease. Lab Invest 72:619-637, 1995
19. Tahara H: Fibroblasts genetically engineered to secrete interleuken-12 can suppress tumor growth and induce anti-tumor immunity to a murine melanoma in vivo. Cancer Res 54:182-189, 1994